Clinical

The 2019 EURETINA Clinical Research Awards have initiated a new funding research Call to support and encourage independent clinical research in the field of retinal… Read More »***EURETINA launch the Retinal Medicine Clinical Research Funding Call***

Clinical researchers in Sydney state that neither ranibizumab nor aflibercept for nAMD are superior to the other regarding the average visual acuity gains and number… Read More »Anti-VEGF treatments between ranibizumab and aflibercept show that neither medication may be superior in head-to-head study

Clinical research for gene editing technology will be aiming to start a Phase I/II interventional trial to treat Leber congenital amaurosis type 10 (LCA10).  LCA10… Read More »CRISPR gene editing technology may initiate LCA clinical research study for Phase I/II

Researchers from the Nuffield Laboratory of Ophthalmology, University of Oxford, UK, demonstrate that clinical data on a choroideremia gene therapy study among 14 UK patients… Read More »Beneficial effects of retinal gene therapy show continuing treatment over 2-year endpoints

Researchers from the University of Miami, in collaboration with Johns Hopkins University, demonstrate that vision loss precedes a loss of mental capacity, suggesting that maintaining… Read More »Visual impairment appears to be adversely associated with cognition – the Salisbury Eye Evaluation Study

Anti-VEGF treatment of exudative age-related macular degeneration has represented a paradigm shift in the medical management of the disease however, not all patients obtain the… Read More »Phase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year

Results from two clinical trials testing a new anti-VEGF molecule against ranibizumab (trade name Lucentis) suggest that clinicians will still need to balance overall efficacy… Read More »Phase III results with novel anti-VEGF molecule suggest that choosing the right treatment for each patient may be challenging

Collaborative research, led by a team at the UCL Institute of Ophthalmology, London, UK, has shown a clear association between a thinner retinal nerve fibre… Read More »Clinical research suggests a thinning retinal nerve fibre layer (RNFL) may be associated with a greater risk of future cognitive decline.

Research led by a team at the Radboud University Medical Center in Nijmegen, the Netherlands, have shown that the response to anti-VEGF medication may arise… Read More »Clinical genetics research into the variability of response to anti-VEGF treatment suggests common gene variants may have a limited contribution